Speaker

Frederic Desdouits

Chief Executive Officer, OranoMed

Frederic Desdouits, Chief Executive Officer at OranoMed, is speaking at 8th Targeted Radiopharmaceuticals Summit Europe 2026 (London, United Kingdom, 1–3 Dec 2026) in the session “Demonstrating the Clinical Potential of Pb-212 Alpha Therapy: Key Learnings from Phase II AlphaMedix Development”.

Conferences: 1
Keynotes: 0
Upcoming: 1

Upcoming appearances

8th Targeted Radiopharmaceuticals Summit Europe 2026
1–3 Dec 2026London, United Kingdom
- SpeakerDemonstrating the Clinical Potential of Pb-212 Alpha Therapy: Key Learnings from Phase II AlphaMedix Development

More speakers at 8th Targeted Radiopharmaceuticals Summit Europe 2026

Friedmund Bachmann
Vice President CMC & Project Lead, OncoOne
Luke Brzozowski
Executive Director - Translational Research & Core Facilities ,Program Sponsor, Theranostics, UHN
Chaitanya Divgi
Senior Expert - Strategic Therapeutic Innovation, Novartis
Kemp Dolliver
Director of Research, Brookline Capital Markets
Rich Edwards
Chief Technology Officer, Nuclide Therapeutics
Waisi Eng
Chief Technology Officer, Norroy North America Inc.

See all 36 speakers on the event page

This profile is built from conference programmes published on kongre.net. It has not been claimed or confirmed by Frederic Desdouits, and it lists only the talks, sessions and presentations named in those programmes.

Is this you? Claim this profile — every request is read by a person before anything is linked.

To ask for a correction or for this profile to be removed, email [email protected].